Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an ...

Hosted by Investor Relations Officer Richard Cathcart, the episode features an in-depth conversation about Mercado Libre's ...

The best blue light glasses effectively filter blue light, reduce glare, and provide comfort for all-day wear. Jaylyn Pruitt has been working with Dotdash Meredith since May 2019 and is currently ...

MSD has acquired cancer therapeutics developer Modifi Biosciences, enhancing its portfolio with preclinical compounds.

The original FDA full approval decision date was 15 October, but this has been delayed. Credit: Tada Images via Shutterstock. Intercept Pharmaceuticals will have to keep waiting for a decision about ...

Light therapy lamps have been found to be an effective treatment for seasonal affective disorder (SAD). Seasonal affective disorder can bring on symptoms like depression, hopelessness, and fatigue, so ...

Harvey Weinstein has been diagnosed with bone cancer, a source close to the incarcerated producer tells CNN. Weinstein’s specific diagnosis is chronic myeloid leukemia, a form of cancer of the bone ...

Edita was diagnosed with chronic myeloid leukaemia (CML) – a form of blood cancer which can develop slowly and affects myeloid cells, which are a type of white blood cell. Unexplained weight ...

These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of ...

The ASC4FIRST trial has shown asciminib, a novel BCR::ABL1 inhibitor, as a promising alternative to current tyrosine kinase inhibitors (TKIs) for chronic phase (CP) chronic myeloid leukaemia (CML).